NEWS

Visuel 2

Exclusive licensing agreement with m8 Pharmaceuticals

m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil.

Jonathan Cohen promoted Director of Regulatory and Industrial Affairs

” It has been almost a year since Jonathan joined Vectans pharma team. Over the past few months, his professional…
IMG_0475

Meeting on ORAVI® /LORAMYC® with Sosei Heptares and FujiFilm Pharma

Vectans Pharma participated to the Commemorative Lecture for new release of ORAVI®/LORAMYC® Mucoadhesive Tablet 50mg, a meeting organized by Sosei…
actus02

Vectans Pharma launches an innovative medecine for treating herpes labialis

About 1 in 10 people suffer from recurring herpes labialis in France. Patients have an average of 3,4 episodes each…
bichat-ph

Vectans Pharma will be attending
Les Entretiens de Bichat

Vectans Pharma will meet Health Care Professionnals during Les Entretiens de Bichat on 8 & 9 October 2018 in Issy-les-Moulineaux.
News-Stefan-Lempereur-2

Dr Stefan Lempereur appointed as Chief Medical Officer

Vectans Pharma announces the appointment of Dr Stefan Lempereur as its new Chief Medical Officer, effective from March 1st 2018.
logo-vectans-bleu-04

ABOUT VECTANS PHARMA

Vectans Pharma is an international pharmaceutical company with an innovative drug delivery technology that brings clear benefits to patients. Through international licensing agreements, Vectans Pharma products are commercialized in the United States, Latin America, Asia and Europe.

CONTACT

+33(0)1.41.21.90.16
[email protected]

230 Bureaux de la colline
92213 SAINT CLOUD
France

Copyright © VECTANS PHARMA